Innovent and Eli Lilly Announce Acceptance of a Supplemental New Drug Application of TYVYT(R) (Sintilimab Injection) in Combination with Gemcitabine and Platinum as First-Line Therapy in Squamous Non-Small Cell Lung Cancer in China

SUZHOU, China, Aug. 12, 2020 -- (Healthcare Sales & Marketing Network) -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the ... Biopharmaceuticals, Oncology, Regulatory Innovent Biologics, Eli Lilly, TYVYT, sintilimab, NSCLC
Source: HSMN NewsFeed - Category: Pharmaceuticals Source Type: news